MAP2K7 and metastatic melanoma: The strength of our study is that it used logistic regression models, and with the analysis we were able to identify independent prognostic factors that have not yet been described in relation to metastatic melanoma treated with BRAF + MEK inhibitors, which are worthy of further investigation.